Alzheimer’s disease therapies in phase II development 2024, by type
As of January 1, 2024, 12 percent of Alzheimer’s disease drugs in clinical trial phase II of development worldwide were targeting synaptic plasticity/neuroprotection pathways. This statistic illustrates Alzheimer’s disease therapies in phase II of development worldwide, by type.